BERKELEY HEIGHTS, N.J., April 17, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,124,593 ('593), which grants claims to a specified method of administration of sapacitabine, Cyclacel's lead drug candidate, with patent exclusivity until July 2030.
